Pharma & Healthcare
Global Monoclonal Antibody for Asthma and COPD Market Research Report 2025
- Sep 24, 25
- ID: 521091
- Pages: 91
- Figures: 94
- Views: 5
Report Scope
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Asthma and COPD.
The Monoclonal Antibody for Asthma and COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibody for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody for Asthma and COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Teva Pharmaceuticals
Sanofi
AstraZeneca
GlaxoSmithKline
Roche
Amgen
Abacus Medicine
Swixx Biopharma
OriFarm
Aphria
Novartis
Segment by Type
Reslizumab
Dupilumab
Benralizumab
Mepolizumab
Tezepelumab-ekko
Omalizumab
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibody for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibody for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Asthma and COPD.
The Monoclonal Antibody for Asthma and COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibody for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody for Asthma and COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Teva Pharmaceuticals
Sanofi
AstraZeneca
GlaxoSmithKline
Roche
Amgen
Abacus Medicine
Swixx Biopharma
OriFarm
Aphria
Novartis
Segment by Type
Reslizumab
Dupilumab
Benralizumab
Mepolizumab
Tezepelumab-ekko
Omalizumab
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibody for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibody for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Monoclonal Antibody for Asthma and COPD Market Overview
1.1 Product Definition
1.2 Monoclonal Antibody for Asthma and COPD by Type
1.2.1 Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031)
1.2.2 Reslizumab
1.2.3 Dupilumab
1.2.4 Benralizumab
1.2.5 Mepolizumab
1.2.6 Tezepelumab-ekko
1.2.7 Omalizumab
1.2.8 Others
1.3 Monoclonal Antibody for Asthma and COPD by Application
1.3.1 Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibody for Asthma and COPD Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody for Asthma and COPD Revenue 2020-2031
1.4.2 Global Monoclonal Antibody for Asthma and COPD Sales 2020-2031
1.4.3 Global Monoclonal Antibody for Asthma and COPD Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Monoclonal Antibody for Asthma and COPD Market Competition by Manufacturers
2.1 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
2.2 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Monoclonal Antibody for Asthma and COPD Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry
2.8 Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody for Asthma and COPD Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody for Asthma and COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody for Asthma and COPD Market Scenario by Region
3.1 Global Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2031
3.2.1 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2025
3.2.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2026-2031
3.3 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2031
3.3.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2025
3.3.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2026-2031
3.4 North America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.4.3 North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.5.3 Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2031)
3.6.3 Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.7.3 Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.8.3 Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2031)
4.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2025)
4.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2026-2031)
4.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2031)
4.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2025)
4.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2026-2031)
4.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2031)
4.3 Global Monoclonal Antibody for Asthma and COPD Price by Type (2020-2031)
5 Segment by Application
5.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2031)
5.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2025)
5.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2026-2031)
5.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2031)
5.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2031)
5.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2025)
5.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2026-2031)
5.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2031)
5.3 Global Monoclonal Antibody for Asthma and COPD Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Teva Pharmaceuticals
6.1.1 Teva Pharmaceuticals Company Information
6.1.2 Teva Pharmaceuticals Description and Business Overview
6.1.3 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product Portfolio
6.1.5 Teva Pharmaceuticals Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Monoclonal Antibody for Asthma and COPD Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Monoclonal Antibody for Asthma and COPD Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Roche
6.5.1 Roche Company Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Roche Monoclonal Antibody for Asthma and COPD Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Company Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amgen Monoclonal Antibody for Asthma and COPD Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Abacus Medicine
6.7.1 Abacus Medicine Company Information
6.7.2 Abacus Medicine Description and Business Overview
6.7.3 Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Abacus Medicine Monoclonal Antibody for Asthma and COPD Product Portfolio
6.7.5 Abacus Medicine Recent Developments/Updates
6.8 Swixx Biopharma
6.8.1 Swixx Biopharma Company Information
6.8.2 Swixx Biopharma Description and Business Overview
6.8.3 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product Portfolio
6.8.5 Swixx Biopharma Recent Developments/Updates
6.9 OriFarm
6.9.1 OriFarm Company Information
6.9.2 OriFarm Description and Business Overview
6.9.3 OriFarm Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.9.4 OriFarm Monoclonal Antibody for Asthma and COPD Product Portfolio
6.9.5 OriFarm Recent Developments/Updates
6.10 Aphria
6.10.1 Aphria Company Information
6.10.2 Aphria Description and Business Overview
6.10.3 Aphria Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Aphria Monoclonal Antibody for Asthma and COPD Product Portfolio
6.10.5 Aphria Recent Developments/Updates
6.11 Novartis
6.11.1 Novartis Company Information
6.11.2 Novartis Description and Business Overview
6.11.3 Novartis Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Novartis Monoclonal Antibody for Asthma and COPD Product Portfolio
6.11.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody for Asthma and COPD Industry Chain Analysis
7.2 Monoclonal Antibody for Asthma and COPD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody for Asthma and COPD Production Mode & Process Analysis
7.4 Monoclonal Antibody for Asthma and COPD Sales and Marketing
7.4.1 Monoclonal Antibody for Asthma and COPD Sales Channels
7.4.2 Monoclonal Antibody for Asthma and COPD Distributors
7.5 Monoclonal Antibody for Asthma and COPD Customer Analysis
8 Monoclonal Antibody for Asthma and COPD Market Dynamics
8.1 Monoclonal Antibody for Asthma and COPD Industry Trends
8.2 Monoclonal Antibody for Asthma and COPD Market Drivers
8.3 Monoclonal Antibody for Asthma and COPD Market Challenges
8.4 Monoclonal Antibody for Asthma and COPD Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Monoclonal Antibody for Asthma and COPD by Type
1.2.1 Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031)
1.2.2 Reslizumab
1.2.3 Dupilumab
1.2.4 Benralizumab
1.2.5 Mepolizumab
1.2.6 Tezepelumab-ekko
1.2.7 Omalizumab
1.2.8 Others
1.3 Monoclonal Antibody for Asthma and COPD by Application
1.3.1 Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibody for Asthma and COPD Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody for Asthma and COPD Revenue 2020-2031
1.4.2 Global Monoclonal Antibody for Asthma and COPD Sales 2020-2031
1.4.3 Global Monoclonal Antibody for Asthma and COPD Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Monoclonal Antibody for Asthma and COPD Market Competition by Manufacturers
2.1 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
2.2 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Monoclonal Antibody for Asthma and COPD Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry
2.8 Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody for Asthma and COPD Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody for Asthma and COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody for Asthma and COPD Market Scenario by Region
3.1 Global Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2031
3.2.1 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2025
3.2.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2026-2031
3.3 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2031
3.3.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2025
3.3.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2026-2031
3.4 North America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.4.3 North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.5.3 Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2031)
3.6.3 Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.7.3 Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)
3.8.3 Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2031)
4.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2025)
4.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2026-2031)
4.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2031)
4.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2025)
4.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2026-2031)
4.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2031)
4.3 Global Monoclonal Antibody for Asthma and COPD Price by Type (2020-2031)
5 Segment by Application
5.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2031)
5.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2025)
5.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2026-2031)
5.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2031)
5.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2031)
5.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2025)
5.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2026-2031)
5.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2031)
5.3 Global Monoclonal Antibody for Asthma and COPD Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Teva Pharmaceuticals
6.1.1 Teva Pharmaceuticals Company Information
6.1.2 Teva Pharmaceuticals Description and Business Overview
6.1.3 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product Portfolio
6.1.5 Teva Pharmaceuticals Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Monoclonal Antibody for Asthma and COPD Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.3.4 AstraZeneca Monoclonal Antibody for Asthma and COPD Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Roche
6.5.1 Roche Company Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Roche Monoclonal Antibody for Asthma and COPD Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Company Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amgen Monoclonal Antibody for Asthma and COPD Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Abacus Medicine
6.7.1 Abacus Medicine Company Information
6.7.2 Abacus Medicine Description and Business Overview
6.7.3 Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Abacus Medicine Monoclonal Antibody for Asthma and COPD Product Portfolio
6.7.5 Abacus Medicine Recent Developments/Updates
6.8 Swixx Biopharma
6.8.1 Swixx Biopharma Company Information
6.8.2 Swixx Biopharma Description and Business Overview
6.8.3 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product Portfolio
6.8.5 Swixx Biopharma Recent Developments/Updates
6.9 OriFarm
6.9.1 OriFarm Company Information
6.9.2 OriFarm Description and Business Overview
6.9.3 OriFarm Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.9.4 OriFarm Monoclonal Antibody for Asthma and COPD Product Portfolio
6.9.5 OriFarm Recent Developments/Updates
6.10 Aphria
6.10.1 Aphria Company Information
6.10.2 Aphria Description and Business Overview
6.10.3 Aphria Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Aphria Monoclonal Antibody for Asthma and COPD Product Portfolio
6.10.5 Aphria Recent Developments/Updates
6.11 Novartis
6.11.1 Novartis Company Information
6.11.2 Novartis Description and Business Overview
6.11.3 Novartis Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Novartis Monoclonal Antibody for Asthma and COPD Product Portfolio
6.11.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody for Asthma and COPD Industry Chain Analysis
7.2 Monoclonal Antibody for Asthma and COPD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody for Asthma and COPD Production Mode & Process Analysis
7.4 Monoclonal Antibody for Asthma and COPD Sales and Marketing
7.4.1 Monoclonal Antibody for Asthma and COPD Sales Channels
7.4.2 Monoclonal Antibody for Asthma and COPD Distributors
7.5 Monoclonal Antibody for Asthma and COPD Customer Analysis
8 Monoclonal Antibody for Asthma and COPD Market Dynamics
8.1 Monoclonal Antibody for Asthma and COPD Industry Trends
8.2 Monoclonal Antibody for Asthma and COPD Market Drivers
8.3 Monoclonal Antibody for Asthma and COPD Market Challenges
8.4 Monoclonal Antibody for Asthma and COPD Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation by Manufacturers in 2024
Table 4. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application
Table 12. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Asthma and COPD as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 18. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2025)
Table 19. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 20. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2026-2031)
Table 21. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2025)
Table 23. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2026-2031)
Table 25. North America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 27. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 28. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 32. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 33. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2020-2025)
Table 51. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2026-2031)
Table 52. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2025)
Table 53. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2026-2031)
Table 54. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2025)
Table 57. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2026-2031)
Table 58. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2025)
Table 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2026-2031)
Table 60. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2020-2025)
Table 61. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2026-2031)
Table 62. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2025)
Table 63. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2026-2031)
Table 64. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2025)
Table 67. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2026-2031)
Table 68. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2025)
Table 69. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2026-2031)
Table 70. Teva Pharmaceuticals Company Information
Table 71. Teva Pharmaceuticals Description and Business Overview
Table 72. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product
Table 74. Teva Pharmaceuticals Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sanofi Monoclonal Antibody for Asthma and COPD Product
Table 79. Sanofi Recent Developments/Updates
Table 80. AstraZeneca Company Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Monoclonal Antibody for Asthma and COPD Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. GlaxoSmithKline Company Information
Table 86. GlaxoSmithKline Description and Business Overview
Table 87. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product
Table 89. GlaxoSmithKline Recent Developments/Updates
Table 90. Roche Company Information
Table 91. Roche Description and Business Overview
Table 92. Roche Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Roche Monoclonal Antibody for Asthma and COPD Product
Table 94. Roche Recent Developments/Updates
Table 95. Amgen Company Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Amgen Monoclonal Antibody for Asthma and COPD Product
Table 99. Amgen Recent Developments/Updates
Table 100. Abacus Medicine Company Information
Table 101. Abacus Medicine Description and Business Overview
Table 102. Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Abacus Medicine Monoclonal Antibody for Asthma and COPD Product
Table 104. Abacus Medicine Recent Developments/Updates
Table 105. Swixx Biopharma Company Information
Table 106. Swixx Biopharma Description and Business Overview
Table 107. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product
Table 109. Swixx Biopharma Recent Developments/Updates
Table 110. OriFarm Company Information
Table 111. OriFarm Description and Business Overview
Table 112. OriFarm Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. OriFarm Monoclonal Antibody for Asthma and COPD Product
Table 114. OriFarm Recent Developments/Updates
Table 115. Aphria Company Information
Table 116. Aphria Description and Business Overview
Table 117. Aphria Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Aphria Monoclonal Antibody for Asthma and COPD Product
Table 119. Aphria Recent Developments/Updates
Table 120. Novartis Company Information
Table 121. Novartis Description and Business Overview
Table 122. Novartis Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Novartis Monoclonal Antibody for Asthma and COPD Product
Table 124. Novartis Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Monoclonal Antibody for Asthma and COPD Distributors List
Table 128. Monoclonal Antibody for Asthma and COPD Customers List
Table 129. Monoclonal Antibody for Asthma and COPD Market Trends
Table 130. Monoclonal Antibody for Asthma and COPD Market Drivers
Table 131. Monoclonal Antibody for Asthma and COPD Market Challenges
Table 132. Monoclonal Antibody for Asthma and COPD Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibody for Asthma and COPD
Figure 2. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Monoclonal Antibody for Asthma and COPD Market Share by Type: 2024 & 2031
Figure 4. Reslizumab Product Picture
Figure 5. Dupilumab Product Picture
Figure 6. Benralizumab Product Picture
Figure 7. Mepolizumab Product Picture
Figure 8. Tezepelumab-ekko Product Picture
Figure 9. Omalizumab Product Picture
Figure 10. Others Product Picture
Figure 11. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2020-2031) & (US$ Million)
Figure 12. Global Monoclonal Antibody for Asthma and COPD Market Share by Application: 2024 & 2031
Figure 13. Hospital
Figure 14. Clinic
Figure 15. Others
Figure 16. Global Monoclonal Antibody for Asthma and COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Monoclonal Antibody for Asthma and COPD Market Size (2020-2031) & (US$ Million)
Figure 18. Global Monoclonal Antibody for Asthma and COPD Sales (2020-2031) & (K Units)
Figure 19. Global Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) & (2020-2031)
Figure 20. Monoclonal Antibody for Asthma and COPD Report Years Considered
Figure 21. Monoclonal Antibody for Asthma and COPD Sales Share by Manufacturers in 2024
Figure 22. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players: Market Share by Revenue in Monoclonal Antibody for Asthma and COPD in 2024
Figure 24. Monoclonal Antibody for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 27. North America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 28. United States Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 31. Europe Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 32. Germany Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2031)
Figure 39. China Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. China Taiwan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 47. Latin America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 48. Mexico Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Colombia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)
Figure 58. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)
Figure 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)
Figure 61. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)
Figure 62. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2031)
Figure 63. Monoclonal Antibody for Asthma and COPD Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation by Manufacturers in 2024
Table 4. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application
Table 12. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Asthma and COPD as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 18. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2025)
Table 19. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 20. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2026-2031)
Table 21. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2025)
Table 23. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2026-2031)
Table 25. North America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 27. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 28. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 32. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 33. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2020-2025)
Table 51. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2026-2031)
Table 52. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2025)
Table 53. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2026-2031)
Table 54. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2025)
Table 57. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2026-2031)
Table 58. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2025)
Table 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2026-2031)
Table 60. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2020-2025)
Table 61. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2026-2031)
Table 62. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2025)
Table 63. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2026-2031)
Table 64. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2025)
Table 67. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2026-2031)
Table 68. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2025)
Table 69. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2026-2031)
Table 70. Teva Pharmaceuticals Company Information
Table 71. Teva Pharmaceuticals Description and Business Overview
Table 72. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product
Table 74. Teva Pharmaceuticals Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sanofi Monoclonal Antibody for Asthma and COPD Product
Table 79. Sanofi Recent Developments/Updates
Table 80. AstraZeneca Company Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Monoclonal Antibody for Asthma and COPD Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. GlaxoSmithKline Company Information
Table 86. GlaxoSmithKline Description and Business Overview
Table 87. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product
Table 89. GlaxoSmithKline Recent Developments/Updates
Table 90. Roche Company Information
Table 91. Roche Description and Business Overview
Table 92. Roche Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Roche Monoclonal Antibody for Asthma and COPD Product
Table 94. Roche Recent Developments/Updates
Table 95. Amgen Company Information
Table 96. Amgen Description and Business Overview
Table 97. Amgen Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Amgen Monoclonal Antibody for Asthma and COPD Product
Table 99. Amgen Recent Developments/Updates
Table 100. Abacus Medicine Company Information
Table 101. Abacus Medicine Description and Business Overview
Table 102. Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Abacus Medicine Monoclonal Antibody for Asthma and COPD Product
Table 104. Abacus Medicine Recent Developments/Updates
Table 105. Swixx Biopharma Company Information
Table 106. Swixx Biopharma Description and Business Overview
Table 107. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product
Table 109. Swixx Biopharma Recent Developments/Updates
Table 110. OriFarm Company Information
Table 111. OriFarm Description and Business Overview
Table 112. OriFarm Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. OriFarm Monoclonal Antibody for Asthma and COPD Product
Table 114. OriFarm Recent Developments/Updates
Table 115. Aphria Company Information
Table 116. Aphria Description and Business Overview
Table 117. Aphria Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Aphria Monoclonal Antibody for Asthma and COPD Product
Table 119. Aphria Recent Developments/Updates
Table 120. Novartis Company Information
Table 121. Novartis Description and Business Overview
Table 122. Novartis Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Novartis Monoclonal Antibody for Asthma and COPD Product
Table 124. Novartis Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Monoclonal Antibody for Asthma and COPD Distributors List
Table 128. Monoclonal Antibody for Asthma and COPD Customers List
Table 129. Monoclonal Antibody for Asthma and COPD Market Trends
Table 130. Monoclonal Antibody for Asthma and COPD Market Drivers
Table 131. Monoclonal Antibody for Asthma and COPD Market Challenges
Table 132. Monoclonal Antibody for Asthma and COPD Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibody for Asthma and COPD
Figure 2. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Monoclonal Antibody for Asthma and COPD Market Share by Type: 2024 & 2031
Figure 4. Reslizumab Product Picture
Figure 5. Dupilumab Product Picture
Figure 6. Benralizumab Product Picture
Figure 7. Mepolizumab Product Picture
Figure 8. Tezepelumab-ekko Product Picture
Figure 9. Omalizumab Product Picture
Figure 10. Others Product Picture
Figure 11. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2020-2031) & (US$ Million)
Figure 12. Global Monoclonal Antibody for Asthma and COPD Market Share by Application: 2024 & 2031
Figure 13. Hospital
Figure 14. Clinic
Figure 15. Others
Figure 16. Global Monoclonal Antibody for Asthma and COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Monoclonal Antibody for Asthma and COPD Market Size (2020-2031) & (US$ Million)
Figure 18. Global Monoclonal Antibody for Asthma and COPD Sales (2020-2031) & (K Units)
Figure 19. Global Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) & (2020-2031)
Figure 20. Monoclonal Antibody for Asthma and COPD Report Years Considered
Figure 21. Monoclonal Antibody for Asthma and COPD Sales Share by Manufacturers in 2024
Figure 22. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players: Market Share by Revenue in Monoclonal Antibody for Asthma and COPD in 2024
Figure 24. Monoclonal Antibody for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 27. North America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 28. United States Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 31. Europe Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 32. Germany Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2031)
Figure 39. China Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. China Taiwan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 47. Latin America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 48. Mexico Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Colombia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)
Figure 58. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)
Figure 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)
Figure 61. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)
Figure 62. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2031)
Figure 63. Monoclonal Antibody for Asthma and COPD Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global LED Light Housing Market Research Report 2025
Sep 24, 25
Global Side Emitting LED Strip Light Market Research Report 2025
Sep 24, 25
Global Medium and Low Voltage Unshielded Cable Market Research Report 2025
Sep 24, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232